VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preserving interspinous spacer for the treatment of moderate spinal stenosis. Vertiflex Inc was founded in 2005 and is headquartered in California, USA.
Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota.
Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae aggregates the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.
SGB is a fully-integrated bioenergy crop company using molecular breeding and biotechnology to develop and produce elite hybrid seeds of Jatropha as a low-cost feedstock for biodiesel, bio-jet fuel, and specialty chemicals. With the largest and most diverse library of Jatropha genetic material, SGB is turning the opportunities of Jatropha into reality through a world-class leadership team, leading-edge science and genetics, and expertise in agronomy and plantation management. SGB has been named one of the Top 5 Renewable Jet Fuel Supply Chain Companies in the World by The Carbon War Room (2011), one of the Top 50 Companies in Bioenergy for three consecutive years (2009, 2010, and 2011), and the 2010 Feedstock Domestication Project of the Year by Biofuels Digest and one of the Top 200 Going Green Private Companies in the World by Always On.
Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications.
AxioMed Spine Corporation was formed in 2001 to develop products with a goal of restoring spinal function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Since its inception, AxioMed has secured over $34M in private equity financing from prestigious venture capitalists. The company´s Freedom® Lumbar Disc has been developed and clinical trials initiated. The company is headed by CEO, Patrick McBrayer, who joined AxioMed in early 2006. Mr. McBrayer along with founder and COO, James Kuras, lead an experienced management and development team with significant history and expertise in spinal implants, including early artificial disc development efforts. Company employment includes professionals with extensive spine and engineering experience. The team is augmented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company´s headquarters include product development and testing, clinical and regulatory affairs, and manufacturing. AxioMed will leverage its background in lumbar disc replacement with an ongoing development project for the cervical spine.
Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications.
Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.
Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota.
Tioga Pharmaceuticals, Inc. develops therapies for the treatment of gastrointestinal diseases. Its product includes asimadoline, an orally administered small molecule therapeutic for the treatment of irritable bowel syndrome and functional dyspepsia. The company was founded in 2005 and is based in San Diego, California.
SGB is a fully-integrated bioenergy crop company using molecular breeding and biotechnology to develop and produce elite hybrid seeds of Jatropha as a low-cost feedstock for biodiesel, bio-jet fuel, and specialty chemicals. With the largest and most diverse library of Jatropha genetic material, SGB is turning the opportunities of Jatropha into reality through a world-class leadership team, leading-edge science and genetics, and expertise in agronomy and plantation management. SGB has been named one of the Top 5 Renewable Jet Fuel Supply Chain Companies in the World by The Carbon War Room (2011), one of the Top 50 Companies in Bioenergy for three consecutive years (2009, 2010, and 2011), and the 2010 Feedstock Domestication Project of the Year by Biofuels Digest and one of the Top 200 Going Green Private Companies in the World by Always On.
InnoPharma, LLC. Founded in 2005, is a privately held pharmaceutical research and development (R&D) company, based in Piscataway, New Jersey.
CAS Medical Systems is dedicated to the design and manufacture of innovative, non-invasive technologies and products vital to patient care in the most challenging clinical environments. With a reputation for the highest quality products available in the markets it serves, CASMED products are used by clinicians worldwide.
VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preserving interspinous spacer for the treatment of moderate spinal stenosis. Vertiflex Inc was founded in 2005 and is headquartered in California, USA.
AxioMed Spine Corporation was formed in 2001 to develop products with a goal of restoring spinal function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Since its inception, AxioMed has secured over $34M in private equity financing from prestigious venture capitalists. The company´s Freedom® Lumbar Disc has been developed and clinical trials initiated. The company is headed by CEO, Patrick McBrayer, who joined AxioMed in early 2006. Mr. McBrayer along with founder and COO, James Kuras, lead an experienced management and development team with significant history and expertise in spinal implants, including early artificial disc development efforts. Company employment includes professionals with extensive spine and engineering experience. The team is augmented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company´s headquarters include product development and testing, clinical and regulatory affairs, and manufacturing. AxioMed will leverage its background in lumbar disc replacement with an ongoing development project for the cervical spine.
Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.
NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.
Altair Therapeutics was a biopharmaceutical company that focused on developing therapeutics to treat human respiratory diseases.
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.
Virdante Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes drugs for autoimmune and inflammatory diseases. It offers antibody and Fc-fusion drugs to treat auto-immune diseases. The company was formerly known as Centaurus Pharmaceuticals and changed its name to Virdante Pharmaceuticals, Inc. in April, 2008. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercial sale of prescription drug products based on dermal drug delivery platforms. It offers HYDRO 40 foam, a dry skin treatment product; tersi foam, a leave-on foam indicated for the treatment of seborrheic dermatitis and tinea versicolor; rinnovi nail system, a prescription nail system that is designed to clean, treat, and protect diseased, damaged, brittle, and ingrown nails; and cleanse and treat, a pad delivery technology system for the treatment of acne. Quinnova Pharmaceuticals, Inc. was founded in 2003 and is based in Newtown, Pennsylvania.
Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota.
Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States.
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.
Clarus Therapeutics is a biopharmaceutical company that develops androgen-based medicines for men and women. It offers OriTex, a proprietary oral testosterone product for use in men with low testosterone levels.
Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome. Tranzyme Pharma is based in North Carolina, United States.
Leptos Biomedical offers a proprietary neuromodulation therapy solution for chronic obesity. The company delivers its treatment, which involves the electrical activation of a nerve in the autonomic nervous system via a pacemaker-type device. Leptos Biomedical was founded in 2002 and is based in Fridley, Minnesota.
Softscope Medical Technologies develops endoscopic products. The company is focused on developing CROS enabled device that makes passage of a colonoscope; and CROS device for small bowel enteroscopy. Softscope Medical Technologies was founded in 2003 and is based in Minnetonka, Minnesota.
Elron Ventures is an early-stage investor committed to turning promising ideas into global industry leaders, with a proven track record of investments and successful M&As worldwide. Elron invests in cyber security and B2B software. Since its establishment in 1962, Elron stands on the forefront of Israeli innovation both as a founder and early investor in companies across various industries such as Elbit, Medingo, Given Imaging, Cloudyn, Cyber Secdo, and Alcide.
Galil Medical is a new era of minimally invasive cryotherapy solutions that enhance patient quality of life. Galil Medical’s technology involves freezing and ablating diseased tissue in a technique referred to as cryotherapy, also referred to as cryoablation and cryosurgery. Galil Medical cryotherapy systems use compressed Argon gas to produce extremely low temperatures. As the gas passes through the cryoablation needle, the tip of the needle is cooled, forming an iceball, which engulfs the tumor and destroys the tissue. A variety of needle types is available to sculpt a freeze zone conformed to the tumor size and shape. Galil Medical cryosurgical systems precisely deliver sub-zero temperatures to target tissue with the aid of patented 17-gauge cryoablation needles and high-resolution imaging for the cryosurgical ablation of benign and cancerous tumors. Cryotherapy ablation has been widely used for prostate cancer treatment and kidney cancer treatment. New ablation treatments for various other tumors are being developed in the Women’s Health and Interventional Radiology markets.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercial sale of prescription drug products based on dermal drug delivery platforms. It offers HYDRO 40 foam, a dry skin treatment product; tersi foam, a leave-on foam indicated for the treatment of seborrheic dermatitis and tinea versicolor; rinnovi nail system, a prescription nail system that is designed to clean, treat, and protect diseased, damaged, brittle, and ingrown nails; and cleanse and treat, a pad delivery technology system for the treatment of acne. Quinnova Pharmaceuticals, Inc. was founded in 2003 and is based in Newtown, Pennsylvania.
Solstice Neurosciences is a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. Solstice's first product named Myobloc® (rimabotulinumtoxinB) Injection in the U.S. and NeuroBloc® (Botulinum Toxin Type B) Injectable Solution in select overseas markets, represents the only botulinum toxin type B currently available to physicians and patients worldwide.
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.
Clarus Therapeutics is a biopharmaceutical company that develops androgen-based medicines for men and women. It offers OriTex, a proprietary oral testosterone product for use in men with low testosterone levels.
Solstice Neurosciences is a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. Solstice's first product named Myobloc® (rimabotulinumtoxinB) Injection in the U.S. and NeuroBloc® (Botulinum Toxin Type B) Injectable Solution in select overseas markets, represents the only botulinum toxin type B currently available to physicians and patients worldwide.
Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota.
Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome. Tranzyme Pharma is based in North Carolina, United States.
AxioMed Spine Corporation was formed in 2001 to develop products with a goal of restoring spinal function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Since its inception, AxioMed has secured over $34M in private equity financing from prestigious venture capitalists. The company´s Freedom® Lumbar Disc has been developed and clinical trials initiated. The company is headed by CEO, Patrick McBrayer, who joined AxioMed in early 2006. Mr. McBrayer along with founder and COO, James Kuras, lead an experienced management and development team with significant history and expertise in spinal implants, including early artificial disc development efforts. Company employment includes professionals with extensive spine and engineering experience. The team is augmented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company´s headquarters include product development and testing, clinical and regulatory affairs, and manufacturing. AxioMed will leverage its background in lumbar disc replacement with an ongoing development project for the cervical spine.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.
Clarus Therapeutics is a biopharmaceutical company that develops androgen-based medicines for men and women. It offers OriTex, a proprietary oral testosterone product for use in men with low testosterone levels.
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.
OsteoBiologics is a biotechnology company. It engages in the development and manufacture of bio-absorbable polymeric scaffolds, films, and related instrumentations for the repair and replacement of bone, soft tissue, and articular cartilage. It provides ACTAEON, a tissue evaluation system, which determines the degree and scope of articular cartilage degeneration. It also manufactures custom parts. OsteoBiologics was founded in 1993 and is headquartered in San Antonio, Texas.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.